skinny.

Latest / Breastcancer.org Podcast

SABCS 2019: Tucatinib: A New Standard of Care for HER2-Positive Metastatic Breast Cancer?

Dr. Rashmi Murthy, assistant professor of breast medical oncology at the University of Texas MD Anderson Cancer Center in Houston, discusses the results of the HER2CLIMB study that she presented at the 2019 San Antonio Breast Cancer Symposium showing that the experimental medicine tucatinib offers benefits to people diagnosed with HER2-positive metastatic breast cancer and may be a new standard of care.

Listen to the episode to hear Dr. Murthy explain:

a summary of the study results

why this study included people with brain metastases

the side effects of tucatinib

why she thinks the results…

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.